Company news

AdAlta Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4C - quarterly

January 30, 2020

AdAlta Granted US Patent for AD-214

January 29, 2020

AD-214 Phase I strategy and timing update

January 13, 2020

AdAlta awarded Biomedical Translation Bridge Funding

December 12, 2019

GLP Toxicology study results

October 28, 2019

Tim Oldham Appointed as Chief Executive Officer

October 8, 2019

Receipt of R&D Tax Incentive

September 17, 2019

AdAlta secures licensing deal with GE Healthcare

September 15, 2019

Executive team changes

August 11, 2019

GLP toxicology study commences

July 15, 2019

Entitlement Offer Results and Shortfall Notification

June 14, 2019

Completion of Capital Raise - $5 million

May 23, 2019

AD-214 manufacturing update

May 2, 2019

Manufacturing update

January 28, 2019

Appendix 4C - Quarter ended 30 September 2018

October 16, 2018

Manufacturing Update

October 14, 2018

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

Investor presentation and conference call

July 31, 2018

Appendix 4C - Quarter ended 30 June 2018

July 15, 2018

Completion of Capital Raise - $4.25m to advance AD-214

July 12, 2018

AdAlta secures key manufacturing agreements for AD-214

June 4, 2018

Appendix 4C - Quarter Ended 31 March 2018

April 22, 2018

AdAlta to advance improved lung fibrosis therapy, AD-214

April 17, 2018

AdAlta collaborator awarded NHMRC grant

December 6, 2017

AdAlta granted key Australian Patent

November 16, 2017

Commercial agreement with XL-protein

November 13, 2017

Conference Presentation

October 31, 2017

Results of multi-dose toxicology study

September 18, 2017

AdAlta awarded SIEF grant

July 23, 2017

Toxicology study and manufacturing update

July 17, 2017

Presentation of Eye Fobrosis Data at ARVO Meeting

May 8, 2017

AdAlta expands partnership with Alfred Hospital

March 20, 2017

AdAlta receives Orphan Designation for AD-114

January 18, 2017

Positive Pre-clinical Data

January 8, 2017

Commercialisation Agreement with Crossbeta Biosciences

November 7, 2016

Quarterly Review and Appendix 4C

October 26, 2016

Receipt of Innovation Connections Grant

September 13, 2016

Agreement with FujiFilm Diosynth Biotechnologies

September 12, 2016

← Newer news releases

Decks

The 5 newest of 84 decks. Every deck is listed under its year.